Parkinsons sygdom (PS) er en progressiv, neurologisk sygdom som pt. kun kan behandles symptomatisk. RNA-medicin har vist sig som en lovende farmakologisk klasse til sygdomsmodificerende behandling af neurologiske sygdomme. Dette projekt vil udnytte dette til at udvikle antisense oligonukleotider (ASO) med evnen til at stoppe progressionen af PS. Projektet favner ASO screening, forsøg i PS dyremodeller og non-klinisk udvikling og har potentialet til at markant forbedre livet for PS-patienter.

As fossil fuels are phased out, the ongoing energy transition increases the need for power-to-X (PtX) systems providing anciliary services and converting fluctuating wind/solar power to high-value products such as clean fuels. Electricity constitutes up to 80% of the PtX product cost, therefore, high conversion efficiency is critical. The solid oxide electrolysis (SOE) technology has 40% higher fuel production efficiency than competing alternatives, however limited lifetime is a barrier to SOE commercialization. The ROAD2X consortium will address this barrier by maturing DynElectro’s newly patented (AC:DC) operation that increases SOE lifetime. Additionally, AC:DC operation improves impurity tolerance and enables dynamic operation, important for balancing renewable power production with power consumption. The project prepares AC:DC operated SOE technology for commercialization by 1) demonstrating robust long-term operation (1 year) of SOE cells and a stack 2) investigate the tested cells and stack to identify how AC:DC operation reduces SOE degradation and improves impurity tolerance 3) demonstrating dynamic operation with a 40 kW SOE system 4) designing a power-to-methanol systems with thermally integrated SOE modules. Notably, the generic AC:DC operation method can be used on existing SOE technology from leading manufacturers, which enables rapid implementation and scaling towards large PtX systems for clean fuel production.